Related Experiment Video
Updated: Feb 2, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
Published on: June 10, 2017
Therapeutic recommendations for early stage Hodgkin lymphomas
Julien Depaus1, Anne Delcourt2, Marc André1
1Department of Haematology, Université catholique de Louvain, CHU UCL Namur, Yvoir, Belgium.
Reducing treatment for early Hodgkin lymphoma (HL) lowers toxicity but the effect on secondary cancers is unclear. Positron emission tomography-computed tomography (PET-CT) aids individualized therapy, guiding treatment intensity based on early response.
Area of Science:
- Oncology
- Radiotherapy
- Pharmacology
Background:
- Combined modality treatment is standard for early Hodgkin lymphoma (HL).
- Recent trials aim to reduce treatment burden (radiotherapy fields/doses, chemotherapy cycles) due to high success rates and late toxicity risks.
- The impact of treatment reduction on secondary malignancy rates is still unclear.
Purpose of the Study:
- To evaluate the impact of reduced treatment strategies on secondary malignancy rates in early-stage Hodgkin lymphoma.
- To assess the role of Positron Emission Tomography-Computed Tomography (PET-CT) in guiding individualized therapy based on early treatment response.
- To explore the potential of novel agents like brentuximab vedotin and checkpoint inhibitors in early-stage HL.
Main Methods:
- Review of clinical trials focusing on reduced radiotherapy and chemotherapy in early-stage Hodgkin lymphoma.
- Analysis of Positron Emission Tomography-Computed Tomography (PET-CT) utility for staging and end-of-treatment assessment.
- Evaluation of randomized clinical trials employing PET-CT response to guide individualized therapy (e.g., after 2-3 cycles of ABVD).
Main Results:
- Treatment reductions in radiotherapy and chemotherapy have been successfully implemented for favorable early-stage patients.
- Early Positron Emission Tomography-Computed Tomography (PET-CT) response after ABVD chemotherapy correlates with final outcome.
- PET-CT guided trials aim to spare radiotherapy for PET-negative patients and intensify treatment for PET-positive patients.
Conclusions:
- Further research is needed to clarify the long-term impact of treatment de-escalation on secondary malignancy rates in Hodgkin lymphoma.
- Positron Emission Tomography-Computed Tomography (PET-CT) is a valuable tool for tailoring therapy in early-stage Hodgkin lymphoma.
- Novel therapeutic agents are under investigation for potential application in early-stage Hodgkin lymphoma treatment paradigms.
Related Concept Videos
Therapeutic Index
Stages of Infection
Stages of General Anesthesia
Stages of Sleep
Before sleep begins, in wakefulness, the brain exhibits primarily beta waves, which are high in frequency and low in amplitude, indicating alertness...
Therapeutic Communication
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...

